Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial

BACKGROUND: The most recent European Association for the Study of the Liver (EASL) 2016 Guidelines on treatment of hepatitis C (HCV), allowed for shortening the course of treatment for some subsets of patients with sofosbuvir/ledipasvir and with grazoprevir/elbasvir based on cutoff baseline HCV RNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Yakoot, Mostafa, Abdo, Alaa M., Abdel-Rehim, Siham, Helmy, Sherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514382/
https://www.ncbi.nlm.nih.gov/pubmed/28647541
http://dx.doi.org/10.1016/j.ebiom.2017.05.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514382/
https://www.ncbi.nlm.nih.gov/pubmed/28647541
http://dx.doi.org/10.1016/j.ebiom.2017.05.011

Ejemplares similares